Interventions

Interventions · cardiorenal medicineSGLT2 inhibitors are proven cardiorenal drugs and plausible geroscience candidates, not established longevity medicinesClinical benefitheart-failure and kidney outcomes improve in selected patientsOlder adultstrial evidence supports benefit across older and nonolder groupsMechanistic interestfuel use, inflammation and cellular stress remain hypothesesLongevity gapno human lifespan-extension claim is establishedEvidence verdict: SGLT2 inhibitors clearly reduce important heart-failure … Read more

Interventions & technologies · mTOR inhibitionRapamycin is a powerful geroscience candidate, not a proven human longevity treatmentModel evidencelate-life lifespan extension is reproducible in miceHuman evidencephysiological signals exist, but no lifespan resultPEARL primary outcomevisceral adiposity did not significantly improveSafety gapoptimal exposure and long-term risks remain unresolvedEvidence verdict: Rapamycin is arguably the most reproducible pharmacologic lifespan-extending intervention … Read more

Interventions & technologies · human senolyticsSenolytics are promising in models, but human evidence is still earlyAnimal evidencesenescent-cell targeting can improve selected modelsHuman signalssmall disease-specific studies show feasibilityBiomarker gapno universal target-engagement test existsLongevity gapno senolytic has extended human lifespanEvidence verdict: Senolytics are compelling in animal models, but human evidence remains early. Dasatinib plus quercetin has shown … Read more

Interventions & technologies · cellular reprogrammingPartial reprogramming is a preclinical rejuvenation strategy, not a human anti-aging treatmentPreclinicalthe strongest systemic findings are from cells and mice, not human trialsIdentity risktoo much reprogramming can erase cell state or create pluripotent cellsDeliverydose, timing, tissue targeting and reversibility remain central problemsClock gapyounger molecular markers do not by themselves prove … Read more